Dec 01, 2021 / 02:15PM GMT
Maneka Mirchandaney - Evercore ISI - Analyst
Awesome. Hi, everyone. This is Maneka Mirchandaney from the Evercore ISI biotech team. Very pleased to be here with Kymera for our next fireside chat. We've got Nello Mainolfi who is President and CEO. Thank you for joining. Really exciting times for Kymera and protein degradation more broadly as well.
Questions and Answers:
Maneka Mirchandaney - Evercore ISI - AnalystTo start, I guess just give us a quick snapshot of where Kymera is right now.
Nello Mainolfi - Kymera Therapeutics, Inc. - Co-Founder, President, & CEO
Yes. Thanks, Maneka, for the invitation. Good morning, everyone.
So yes, exciting time for Kymera. We just announced, I believe, yesterday our third cleared IND of 2021. So it's been a very busy year. So we started the Company with the goal of building completely new drugs using protein degradation and, we believe, has the potential to transform medicines. And I think having now three clinical stage programs, it really makes it feel real.